Agilent Technologies Details LC-MS Methods for Viral Particle Characterization

Agilent Technologies has detailed the application of liquid chromatography-mass spectrometry (LC-MS) for the characterization of viral particles, such as adenoviral and lentiviral vectors. These analytical methods are critical for the research and development of gene therapy products and vaccines.

The company states that LC-MS technology provides in-depth information regarding the structure and composition of viral particles. This data is essential for ensuring the quality and safety of products before their clinical application.

Agilent Technologies offers solutions aimed at assisting researchers and developers in gaining a comprehensive understanding of viral particle protein profiles and the identification of potential impurities. This capability is expected to accelerate the deployment of novel therapeutic agents.

The company's focus remains on delivering analytical tools that enhance precision and efficiency within the life sciences sector. The development of LC-MS techniques for viral particle analysis is part of Agilent's broader strategy to support drug discovery and manufacturing processes.